The inclusion of Cxbladder Triage in a February 2025 amendment to the American Urology Association (AUA) Microhematuria Guideline is set to headline a symposium at the Annual Meeting of the Southeastern Section of the AUA (SESAUA) to be held 12-15 March in Nashville, Tennessee.
 
The SESAUA Meeting is attended by several hundred urologists and is the first opportunity for Pacific Edge to promote Cxbladder Triage since its inclusion in the AUA Microhematuria Guideline. Cxbladder Triage will headline a symposium focused on the use of Triage to risk stratify patients with microhematuria in line with the new AUA guideline¹.
 
In a major amendment to the 2020 microhematuria guideline, the updated guideline now incorporates language for the use of urine-based biomarkers to help avoid cystoscopy in intermediate-risk patients². In support of this, the guideline specifically mentions Cxbladder Triage as the only urine-based biomarker test underpinned by ‘Grade A’ evidence linked to a randomized controlled trial - the STRATA³ Study. The STRATA study demonstrated a first for any urine biomarker, that Cxbladder Triage could safely and effectively reduce cystoscopies by as much as 59% without missing tumors. 
 
With the guideline inclusion and symposium providing a focal point for discussion at the event, Pacific Edge will be hosting a booth in the main hall alongside a range of other targeted activities through which the team will engage with customers and other attendees.
 
The SESAUA symposium will be presented by Dr Zachary Klaassen, Urologic Oncologist and Associate Professor of Urology; Wellstar MCG Health and the Georgia Cancer Center. 

• 12:15 to 1:15 PM, Thursday 13 March (CDT): Cxbladder Triage: Risk Stratification for Patients with Microhematuria (Grand Hyatt, Summit Ballroom AB)

Pacific Edge Chief Executive Dr Peter Meintjes said: “We are excited by the opportunity to promote Cxbladder Triage to urological teams from across the Southeastern Region and the wider US with the support of AUA guideline inclusion language. Importantly the updated recommendation will benefit patients, reducing the burden of unnecessary cystoscopies for those with lower risk, resulting in less patient discomfort and morbidity. Those at higher risk will benefit from improved access to care through reduced waiting times.
 
“While the guideline does not mandate the use of Cxbladder Triage, it is authoritative, reinforcing best practice within the urological industry. As a consequence, Pacific Edge anticipates an uplift in demand for Cxbladder tests as more clinicians begin to observe this new recommendation and incorporate the tests into care pathways.”

¹ Barocas DA, Lotan Y, Matulewicz RS, Raman JD, Westerman ME, Kirkby E, Pak L, Souter L. Updates to Microhematuria: AUA/SUFU Guideline (2025). J Urol. doi: 10.1097/JU.0000000000004490. 

² Changes to the risk-stratification criteria for low, intermediate and high-risk categories have been made as part of the guideline update and increases the percentage of patients that are expected to be classified as intermediate risk up to 70% of the population presenting with microhematuria, according to Pacific Edge’s estimate.

³ Lotan et al. (2024). A Multicenter Prospective Randomized Controlled Trial Comparing Cxbladder Triage to Cystoscopy in Patients With Microhematuria. The Safe Testing of Risk for Asymptomatic Microhematuria Trial. The Journal of Urology Vol 212 1-8 Jul 2024.